Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study

S. Hegewisch-Becker, G. Mendez, J. Chao, R. Nemecek, K. Feeney, E. Van Cutsem, SE. Al-Batran, W. Mansoor, N. Maisey, R. Pazo Cid, M. Burge, D. Perez-Callejo, RW. Hipkin, S. Mukherjee, M. Lei, H. Tang, S. Suryawanshi, RJ. Kelly, NC. Tebbutt

. 2024 ; 42 (17) : 2080-2093. [pub] 20240509

Language English Country United States

Document type Journal Article, Clinical Trial, Phase II, Randomized Controlled Trial, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24013540

PURPOSE: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients with previously untreated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). METHODS: Patients with unresectable, locally advanced or metastatic GC/GEJC were randomly assigned 1:1 to nivolumab + relatlimab (fixed-dose combination) + chemotherapy or nivolumab + chemotherapy. The primary end point was objective response rate (ORR; per RECIST v1.1 by blinded independent central review [BICR]) in patients whose tumors had LAG-3 expression ≥1%. RESULTS: Of 274 patients, 138 were randomly assigned to nivolumab + relatlimab + chemotherapy and 136 to nivolumab + chemotherapy. Median follow-up was 11.9 months. In patients with LAG-3 expression ≥1%, BICR-assessed ORR (95% CI) was 48% (38 to 59) in the nivolumab + relatlimab + chemotherapy arm and 61% (51 to 71) in the nivolumab + chemotherapy arm; median progression-free survival (95% CI) by BICR was 7.0 months (5.8 to 8.4) versus 8.3 months (6.9 to 12.1; hazard ratio [HR], 1.41 [95% CI, 0.97 to 2.05]), and median overall survival (95% CI) was 13.5 months (11.9 to 19.1) versus 16.0 months (10.9 to not estimable; HR, 1.04 [95% CI, 0.70 to 1.54]), respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 69% and 61% of all treated patients, and 42% and 36% of patients discontinued because of any-grade TRAEs in the nivolumab + relatlimab + chemotherapy and nivolumab + chemotherapy arms, respectively. CONCLUSION: RELATIVITY-060 did not meet its primary end point of improved ORR in patients with LAG-3 expression ≥1% when relatlimab was added to nivolumab + chemotherapy compared with nivolumab + chemotherapy. Further studies are needed to address whether adding anti-LAG-3 to anti-PD-1 plus chemotherapy can benefit specific GC/GEJC patient subgroups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013540
003      
CZ-PrNML
005      
20240905133441.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.01636 $2 doi
035    __
$a (PubMed)38723227
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hegewisch-Becker, Susanna $u Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany $1 https://orcid.org/0000000169252327
245    10
$a First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study / $c S. Hegewisch-Becker, G. Mendez, J. Chao, R. Nemecek, K. Feeney, E. Van Cutsem, SE. Al-Batran, W. Mansoor, N. Maisey, R. Pazo Cid, M. Burge, D. Perez-Callejo, RW. Hipkin, S. Mukherjee, M. Lei, H. Tang, S. Suryawanshi, RJ. Kelly, NC. Tebbutt
520    9_
$a PURPOSE: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients with previously untreated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). METHODS: Patients with unresectable, locally advanced or metastatic GC/GEJC were randomly assigned 1:1 to nivolumab + relatlimab (fixed-dose combination) + chemotherapy or nivolumab + chemotherapy. The primary end point was objective response rate (ORR; per RECIST v1.1 by blinded independent central review [BICR]) in patients whose tumors had LAG-3 expression ≥1%. RESULTS: Of 274 patients, 138 were randomly assigned to nivolumab + relatlimab + chemotherapy and 136 to nivolumab + chemotherapy. Median follow-up was 11.9 months. In patients with LAG-3 expression ≥1%, BICR-assessed ORR (95% CI) was 48% (38 to 59) in the nivolumab + relatlimab + chemotherapy arm and 61% (51 to 71) in the nivolumab + chemotherapy arm; median progression-free survival (95% CI) by BICR was 7.0 months (5.8 to 8.4) versus 8.3 months (6.9 to 12.1; hazard ratio [HR], 1.41 [95% CI, 0.97 to 2.05]), and median overall survival (95% CI) was 13.5 months (11.9 to 19.1) versus 16.0 months (10.9 to not estimable; HR, 1.04 [95% CI, 0.70 to 1.54]), respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 69% and 61% of all treated patients, and 42% and 36% of patients discontinued because of any-grade TRAEs in the nivolumab + relatlimab + chemotherapy and nivolumab + chemotherapy arms, respectively. CONCLUSION: RELATIVITY-060 did not meet its primary end point of improved ORR in patients with LAG-3 expression ≥1% when relatlimab was added to nivolumab + chemotherapy compared with nivolumab + chemotherapy. Further studies are needed to address whether adding anti-LAG-3 to anti-PD-1 plus chemotherapy can benefit specific GC/GEJC patient subgroups.
650    _2
$a lidé $7 D006801
650    12
$a nivolumab $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000077594
650    12
$a nádory žaludku $x farmakoterapie $x patologie $x mortalita $7 D013274
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a gastroezofageální junkce $x patologie $7 D004943
650    _2
$a senioři $7 D000368
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a adenokarcinom $x farmakoterapie $x patologie $x mortalita $7 D000230
650    12
$a nádory jícnu $x farmakoterapie $x patologie $x mortalita $7 D004938
650    12
$a protein genu 3 aktivace lymfocytů $7 D000093322
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Mendez, Guillermo $u Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina
700    1_
$a Chao, Joseph $u City of Hope Comprehensive Cancer Center, Duarte, CA $1 https://orcid.org/000000021809504X
700    1_
$a Nemecek, Radim $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Feeney, Kynan $u St John of God Murdoch Hospital, Murdoch, WA, Australia
700    1_
$a Van Cutsem, Eric $u University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium $1 https://orcid.org/0000000263721230 $7 xx0061603
700    1_
$a Al-Batran, Salah-Eddin $u Krankenhaus Nordwest University Cancer Center Frankfurt, and Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt, Germany
700    1_
$a Mansoor, Wasat $u The Christie NHS Foundation Trust, Manchester, United Kingdom $1 https://orcid.org/0000000214774934
700    1_
$a Maisey, Nicholas $u Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom $1 https://orcid.org/0000000189432691
700    1_
$a Pazo Cid, Roberto $u Hospital Miguel Servet, Zaragoza, Spain $1 https://orcid.org/0000000280267391
700    1_
$a Burge, Matthew $u Royal Brisbane & Womens Hospital, Herston, QLD, Australia $1 https://orcid.org/0000000325627806
700    1_
$a Perez-Callejo, David $u Bristol Myers Squibb, Boudry, Switzerland
700    1_
$a Hipkin, R William $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Mukherjee, Sourav $u Bristol Myers Squibb, Princeton, NJ $1 https://orcid.org/0000000316477324
700    1_
$a Lei, Ming $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Tang, Hao $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Suryawanshi, Satyendra $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Kelly, Ronan J $u Baylor University Medical Center, Dallas, TX
700    1_
$a Tebbutt, Niall C $u Austin Health, Heidelberg, VIC, Australia $u University of Melbourne, Melbourne, VIC, Australia
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 42, č. 17 (2024), s. 2080-2093
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38723227 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133435 $b ABA008
999    __
$a ok $b bmc $g 2143385 $s 1225406
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 17 $d 2080-2093 $e 20240509 $i 1527-7755 $m Journal of clinical oncology $n J Clin Oncol $x MED00002596
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options